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ABSTRACT
Several laboratories have reported the reprogramming of
mouse and human fibroblasts into pluripotent cells, using
retroviruses carrying the Oct4, Sox2, Klf4, and c-Myc
transcription factor genes. In these experiments the fre-
quency of reprogramming was lower than 0.1% of the
infected cells, raising the possibility that additional events
are required to induce reprogramming, such as activation
of genes triggered by retroviral insertions. We have there-
fore determined by ligation-mediated polymerase chain
reaction (LM-PCR) the retroviral insertion sites in six
induced pluripotent stem (iPS) cell clones derived from
mouse fibroblasts. Seventy-nine insertion sites were as-
signed to a single mouse genome location. Thirty-five of
these mapped to gene transcription units, whereas 29
insertions landed within 10 kilobases of transcription
start sites. No common insertion site was detected among
the iPS clones studied. Moreover, bioinformatics analyses
revealed no enrichment of a specific gene function, net-
work, or pathway among genes targeted by retroviral
insertions. We conclude that Oct4, Sox2, Klf4, and c-Myc
are sufficient to promote fibroblast-to-iPS cell repro-
gramming and propose that the observed low reprogram-
ming frequencies may have alternative explanations.
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INTRODUCTION
A major goal of current stem cell research is the use of special-
ized cells obtained from patient-derived embryonic stem (ES)
for therapeutic purposes. A giant leap closer to this goal was
made with the discovery that the expression of the transcription
factors Oct4, Sox2, Klf4, and c-Myc induced the reprogram-
ming of mouse skin-derived fibroblasts into induced pluripotent
stem (iPS) cells capable of differentiating into cells of all three
germ layers in teratomas and viable chimeric mice [1]. Similar
results were also reported from other laboratories [2, 3] and for
human cells [4]. Common to these studies is the low frequency
of cell reprogramming, estimated to be approximately 0.1% or
less in all cases. The reason for the observed low frequencies is
not clear, but it is possible that additional genes have to be
activated by insertion of retroviral vectors [5].
Integration sites of gammaretroviruses such as Moloney
leukemia virus are known to be biased toward transcription
start sites of actively transcribed genes [6, 7]. The retroviral
long terminal repeats (LTR) act as promoter/enhancer ele-
ments that can modulate the expression of adjacent genes,
frequently leading to their upregulation [8]. On the basis of
repeated detections of specific genes targeted by integration
in independently derived tumors from retrovirus infected
mice, viral insertion strategies have been used to identify
proto-oncogenes [9]. More recently this strategy was also
successful in identifying genes that help to expand the he-
matopoietic stem cell pool [10, 11].
A recent report concluded that liver- and stomach-derived
iPS cells exhibit no common retroviral integrations, suggest-
ing that expression of Oct4, Sox2, Klf4, and c-Myc is suffi-
cient for reprogramming [12]. However, since these cell
types exhibited only 4–6 integration sites per clone, it is still
possible that fibroblasts, in which a larger number of inte-
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Therefore, to explore whether fibroblast reprogramming re-
quires the activation of additional host genes by retroviral
insertion, we exhaustively determined the integration sites in
six iPS clones obtained from mouse embryo- and tail tip-
derived fibroblasts after infection with retroviral vectors en-
coding the four Yamanaka transcription factors. We identi-
fied and sequenced 93 retroviral insertion sites and mapped
79 insertions to a single location in the mouse genome. No
evidence was obtained for an insertion site common to sev-
eral or all clones, nor was any gene function, gene network,
or canonical pathway preferentially associated with the tar-
geted genes. Our data therefore indicate that Oct4, Sox2,
Klf4, and Myc are sufficient to induce iPS cell reprogram-
ming in fibroblasts, extending the conclusion reached by Aoi
et al. with liver- and stomach-derived cells [12].
MATERIALS AND METHODS
Generation of iPS Cell Clones
Stable iPS cell lines were established as previously described [3].
Briefly, fibroblast cultures were established from postnatal tail-tip
biopsies (for iPS clones A, B, C, and F) or from E14.5 mouse
embryos (iPS clones D and E). cDNAs for murine Oct4, Sox2, and
Klf4, as well as human c-Myc (the constitutively active T58A
mutant), were cloned into the retroviral pMX vector and transfected
into PlatE packaging cells cultured in standard ES medium (Dul-
becco’s modified Eagle’s medium supplemented with 15% fetal
bovine serum, nonessential amino acids, L-glutamine, penicillin-
streptomycin, -mercaptoethanol, and 1,000 U/ml leukemia inhib-
itory factor) on 15-cm plates using Fugene reagent (Roche Applied
Science, Basel, Switzerland, https://www.roche-applied-science.
com). Viral supernatant was harvested at 24, 48, 72, and 96h after
transfection, filtered using a 0.45-m filter, supplemented with 5
g/ml polybrene, and added to the respective fibroblasts cultured on
10-cm plates. Colonies with iPS-like morphology were picked 3–5
weeks later and expanded on irradiated feeder cells in ES medium.
Retroviral Insertion Sites into iPS Cell Clones
Quantified by Southern Blotting
Ten micrograms of genomic DNA of each of the six iPS lines, as
well as of V6.5 ES cells, was digested with BglII (for c-Myc),
BamHI (for Klf4 and Oct4), and HindIII (for Sox2) and separated
on a 0.8% agarose gel. DNA was blotted onto HybondXL mem-
brane (Amersham Biosciences, Piscataway, NJ, http://www.
amersham.com) and hybridized with the respective cDNA probes
labeled with [
32P]-dCTP as described [3].
Mapping of Retroviral Insertion Sites into iPS
Clones
Retroviral insertion sites into iPS were identified by sequencing the
junction fragments between the proviral 5LTR and the host mouse
genome, amplified by LM-PCR essentially as previously reported
[13]. Briefly, DNA extracted from each iPS clone was digested
overnight at 65°C with the frequent cutter restriction enzyme
Tsp509I (Fermentas Life Sciences, Burlington, ON, Canada, http://
www.fermentas.com), which recognizes the tetranucleotide AATT
as its target sequence. The biotin-labeled and LTR-hybridizing
primer LTR-Irev (AGCTGTTCCATCTGTTCTTGGCCCT) was
annealed to the digested DNA and extended with the proofreading
Pfu DNA polymerase (Stratagene, La Jolla, CA, http://www.
stratagene.com). The resulting biotin-tagged double-stranded DNA
fragments were recovered with a magnet after incubating with
streptavidin-coated magnetic beads (Dynabeads M280; Invitrogen,
Carlsbad, CA, http://www.invitrogen.com). An asymmetric linker
cassette (LC) resulting from annealing LC1 (GACCCGGGAGAT-
CTGAATTCAGTGGCACAG) and LC2 (CTGTGCCACTG) oli-
gonucleotides was attached with T4 DNA ligase (Fermentas) to the
biotin-free edge, the resulting DNA was denatured with 0.1 N
NaOH, and single-stranded biotin-labeled DNA was recovered.
Afterward, a first polymerase chain reaction (PCR) (first-step LM-
PCR) was performed with primers LTR-IIrev (GACCTTGATCT-
GAACTTCTC) and LCPCR1for (GACCCGGGAGATCTGAAT-
TC), followed by a nested PCR (second-step LM-PCR) with LTR-
IIIrev (TCCATGCCTTGCAAAATGGC) and LC-PCR2for
(GATCTGAATTCAGTGGCACAG). An LM-PCR internal control
was provided by a 278-base pair (bp) amplicon resulting from the
3LTR located LTR-IIIrev primer up to a retroviral vector backbone
carried Tsp509I target sequence. The positioning for all LM-PCR-
related primers on the resulting amplicons is shown in supporting
information Figure 2. Amplicons for each iPS DNA sample were
shortly electrophoresed in a 2% agarose gel and excised in three
regions, corresponding to high, medium, and low molecular
weight (supporting information Fig. 3). Double-stranded DNA
from these three regions was separately extracted with MinElute
columns (Qiagen, Germantown, MD, http://www1.qiagen.com)
and directly cloned for sequencing into pGEM-T Easy Vector
(Promega, Madison, WI, http://www.promega.com). A prelimi-
nary PCR-based screen on individually grown bacterial colonies
was performed using T7 and SP6 primers that anneal to the
cloning plasmid. Amplicons were electrophoresed in 1% agarose
gels, and their sizes were determined with the Quantity One
software (Bio-Rad, Hercules, CA, http://www.bio-rad.com) us-
ing a Molecular Imager Gel Doc XR System (Bio-Rad). Ampli-
cons differing by more than 5 bp were considered potentially
different and sequenced.
To increase coverage of retroviral insertions, amplicons were
directly sequenced by 454 Genome Sequencer (FLX System; Roche
Applied Science). With that goal, the nested primers for the second-
step LM-PCR described above were replaced by the primers
A-LCPCR2for and B-code-LTR-IVrev, respectively. Primer
A-LCPCR2for (GCCTCCCTCGCGCCATCAGGATCTGAATTC-
AGTGGCACAG) consisted of Roche’s primer A (19-mer, shown in
italics) as required for the high-throughput sequencing, fused to
LCPCR2for. On the other hand, the primer B-code-LTR-IVrev
(GCCTTGCCAGCCCGCTCAGNNNNGCTTGCCAAACCTACA-
GGTG) results from Roche’s primer B (19-mer, shown in italics)
fused to a 4-mer oligonucleotide tag (shown as underlined N) plus
a final LTR-IVrev primer annealing up to 10 nucleotides apart from
the 5LTR edge. The tags correspond to the sequences GATC,
CGAT, TCGA, ATCG, AACG, and CGAA for the A, B, C, D, E,
and F iPS clones, respectively. These tags acts as code bars that
enable unequivocal tracking of the iPS clone contributing each
single amplicon and so allow mixing of the second-step LM-PCR
products from the six iPS clones. This amplicon mix was analyzed
by high-throughput sequencing (Lifesequencing S.L., Paterna,
Spain, http://www.lifesequencing.com) from primer B-code-LTR-
IVrev. The sequences obtained were then processed to determine
the different sequences and their relative abundances.
Amplicons sequenced either after cloning in bacteria or by high
throughput were analyzed for homologies using a publicly available
mouse genome sequence data-base (Ensembl BLAST [http://www.
ensembl.org/Multi/blastview]; Ensembl release 49, March 2008).
Insertion sites obtained by bacterial cloning consisted of amplicons
containing mouse genome sequences flanked by the viral sequence
from the LTR-IIIrev primer up to a CA dinucleotide and the linker
cassette primer LCPCR2for joined by the tetranucleotide AATT
(supporting information Fig. 2). High-throughput sequencing of
amplicons was performed only from B-code-LTR-IVrev primer. In
addition, short amplicons enabled to read even the complementary
sequence to the primer A-LCPCR2for. Eighty-one percent of the
sequences contained the expected AATT linker, with 13% replacing
AATT with AATC, and 1%–3% carried AACT, CACT, or CCCA
sequences. We defined genuine integration sites as those showing at
least 95% sequence homology with the annotated mouse genome
and matching one single genomic locus [6]. The precise location of
the retroviral insertions was defined as the first nucleotide at the
junction between the mouse genome sequence and the proviral
5LTR.
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Tagged Genes
The retroviral insertions were considered to hit gene transcription
units when they landed between the transcription start and stop sites.
Transcription units were considered only when included in the
Refseq database (http://www.ncbi.nlm.nih.gov/RefSeq) or when
they were Ensembl-known transcripts (http://www.ensembl.org).
The retroviral targeted genes included those in which insertions
landed in the transcription unit, as well as those with a transcription
start site closest to the retroviral insertions. The tagged genes were
studied using the Ingenuity Pathway Analysis software (Ingenuity
Systems, Redwood City, CA, http://www.ingenuity.com) to un-
cover enrichments in shared gene functions, pathways, or networks.
Details on the symbols used for the gene network and the connections
as shown in supporting information Figure 6 can be found at https://
analysis.ingenuity.com/pa/info/help/help.htm#legend.htm. To eval-
uate the relevance of our findings, the same software was also
applied to 50 randomly selected groups of mouse genes listed in
the Refseq database. To that end, all genes were arbitrarily
assigned numbers and groups of random numbers selected using
the Random Integer Generator software (Random.org, Dublin,
Ireland, http://www.random.org/integers).
RESULTS
Mapping of Retroviral Insertion Sites in iPS Clones
Reveals No Common Targeted Genes
To test whether there are recurrent integration sites in individ-
ually derived iPS clones generated with retroviral vectors that
might point to as yet unknown collaborating reprogramming
factors, we determined the integration sites of six different iPS
clones derived from murine fibroblasts. Four of these clones (A,
B, C, and D) have previously been determined to be pluripotent
by the formation of teratomas and to generate chimeras after
injection into blastocysts [3]. The other two clones (E and F)
also form teratomas and differentiate into distinct mature cell
types in vitro but have not been tested by blastocyst injection
(M. Stadtfeld and K. Hochedlinger, unpublished data). We first
performed Southern blot analyses with probes against the tran-
scription factors Oct4, Sox2, Klf4, and c-Myc on genomic DNA
extracted from the different iPS clones. The resulting hybrid-
ization bands (supporting information Fig. 1) enabled us to
estimate 6–18 integration sites per iPS clone.
To identify and map the retroviral insertion sites we used
two strategies (Fig. 1). In both approaches we first amplified the
junction fragments between proviral and mouse genomic se-
quences by LM-PCR. The resulting amplicons were then either
cloned into the bacterial plasmid pGEM-T Easy vector followed
by sequencing or directly subjected to high-throughput ampli-
con sequencing with the 454 Genome Sequencer (FLX System;
Roche Applied Science). Bacterial inserts were run on gels and
screened by size (supporting information Fig. 3). Screening
more than 600 bacterial colonies allowed the sequencing of 8, 7,
11, 9, 9, and 14 different junction fragments for iPS clones A–F,
respectively. The coverage of insertion sites relative to those
estimated by Southern blotting was below 80%, probably be-
cause of the predominant amplification of internal control bands
and the heterogeneous PCR amplification efficiency of different
insertions.
The high-throughput sequencing yielded 19,103 sequences
that clustered into 93 amplicons. Every insertion identified by
bacterial cloning was also contained in these amplicons. The
retroviral insertions so identified raised the numbers of inser-
tions per clone to 16, 12, 14, 13, 11, and 27 sites for clones A–F,
respectively. Seventy-nine of those 93 amplicons/insertion sites
could be mapped to specific mouse chromosomes (Table 1).
Unmapped insertions correspond to sequences that aligned with
more than one genomic locus, were too short to be mapped, or
fell into incompletely sequenced genomic stretches.
The retroviral insertion sites were widely distributed
throughout the mouse genome (Fig. 2). Eighteen of the autoso-
mal chromosomes contained at least one insertion, whereas
chromosome 9 and both sex chromosomes had no insertions. No
relationship was observed between the chromosomal length and
the number of retroviral insertions per chromosome. However,
the insertions frequently hit the same chromosomes more than
once. This is exemplified by iPS clone F, where 17 of the 23
insertions mapped were restricted to only four chromosomes (9,
3, 3, and 2 insertions in chromosomes 2, 4, 8, and 16, respec-
tively). Most insertions (Table 1) landed in gene-rich areas, with
Figure 1. Experimental strategy for map-
ping retroviral insertion sites in iPS clones.
DNA was extracted from individual iPS cell
clones, and the fragments between the retro-
viral 5 long terminal repeats and mouse
genomic DNA were amplified by LM-PCR.
The resulting amplicons were then se-
quenced either after cloning in bacterial
plasmids or directly by high-throughput se-
quencing. Retroviral insertions were then de-
termined by performing Ensembl BLAST
searches against a mouse genome database.
Abbreviations: iPS, induced pluripotent
stem; LM-PCR, ligation-mediated polymer-
ase chain reaction.








A1 2B 34483975 Gapvd1 (F) 126777
A2
a 2B 35116715 Gsn (F) 4765 (intron 1)
A3 2H2 156800645 Ndrg3 (R) 17168 (intron 1)
A4 5B1 34869389 Sh3bp2 (F) 956 (intron 1)
A5 11E2 118226086 Timp2 (R)  9447
A6 12F1 103463226 Slc24a4 (F) 95597 (intron 7)
A7 13A5 35914762 Cdyl (R) 163013 (intron 5)
A8 13C3 82707525 Cetn3 (R) 785273
A9 13D1 94774501 Lhfpl2 (R) 53250
A10 18E1 68218379 D18Ertd653e (R) 125468 (intron 1)
A11 18E2 69917746 Ccdc68 (R) 167467
B1 4B3 55541032 Klf4 (F) 4315 (exon 5)
B2 4C7 108060530 OTTMUSG00000008243 (F) 4576
B3 6A1 4368969 Col1a2 (R) 86728
B4 6A1 4453028 Col1a2 (R) 2669
B5 6C1 67216395 Serbp1 (R) 610
B6 7B2 39014778 Plekhf1 (R) 1768
B7 10B3 59289089 Cbara1 (R) 123742 (intron 10)
B8 11B4 76139823 Nxn (R) 72820 (intron 1)
B9 13C3 91061729 Rps23 (F) 1043
B10 16B3 35495343 Pdia5 (F) 4384
C1 1H6 191532238 Ptpn14 (F) 19909
C2 2C3 73209524 Sp9 (R) 14976 (intron 4)
C3 5A1 5709239 Steap2 (R) 14671
C4 8E1 122211976 Wfdc1 (F) 21553 (exon 7)
C5 10C1 78186016 Casp14 (F) 5032
C6 10D3 126748434 Mars (F) 261 (intron 1)
C7 13A3.2 24892273 BC005537 (R) 2879
C8 13D1 105318214 Adamts6 (F) 240299
C9 15A2 11453709 Tars (R) 124296
C10 15D2 47534486 Sh3pxd2a (R) 4405 (intron 1)
C11 19D3 58585304 1700011F14Rik (F) 1188
D1 1H1 163968862 Dnm3 (R) 439299 (intron 17)
D2 2G2 141059046 OTTMUSG00000015674 (F) 940
D3 3F2 95030931 Mllt11 (R) 1294 (intron 1)
D4 5F 118953105 Med13l (F) 57647
D5 5F 112228069 C130026L21Rik (R) 217488
D6 6D2 87823102 Copg (F) 14820
D7 10B3 59415137 Ddit4 (F) 619
D8 11C 88857493 Trim25 (R) 3197
D9 13D1 96319422 F2rl1 (R) 24240
D10 14E4 120697059 Mbnl2 (R) 22130 (intron 1)
D11 16B1 20457862 Abcc5 (R) 31395
D12 18E2 75374255 Dym (R) 195829 (intron 1)
D13 19A 4233573 Pold4 (F) 1595 (exon 4)
E1 3F1 88318454 Lmna (F) 11225
E2 3F3 102331352 Ngfb (F) 57501
E3 4D1 119753070 Edn2 (F) 80736
E4 11E2 118291101 C1qtnf1 (R) 1288 (intron 1)
E5 13A4 33179504 Serpinb1b (R) 3466 (intron 3)
E6 16B2 30596895 BC022623 (R) 2914
E7 17C 47012823 A330017A19Rik (R) 14331
E8 17E4 84368563 Haao (R) 122433
E9 18B3 38009039 Diap1 (R) 86091 (intron 28)
E10 18E3 77736014 Rnf165 (R) 28996
E11 19B 8787296 Slc3a2 (F) 1070 (exon 2)
F1 2B 33120311 Ralgps1 (F) 106695 (intron 7)
F2 2B 39204166 Ppp6c (F) 122347
F3 2C1 52178122 Neb (F) 12532 (intron 7)
F4 2C3 62411646 Fap (F) 432 (intron 1)
F5 2C3 68693947 Lass6 (F) 5667
F6 2F2 125226449 Fbn1 (F) 107280 (intron 7)
F7 2G3 145685702 Rin2 (F) 73986 (intron 8)
F8 2H1 152752982 Fkhl18 (R) 5962
F9 2H2 156219035 2900097C17Rik (R) 470
F10 3E2 68387400 Schip1 (R) 89270 (intron 2)
F11 4A2 11918546 ENSMUSG00000073995 (R) 11097
(continued)
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closest transcription start site. Four insertions mapped to exons
and 31 to introns, with approximately half of the latter being
located in the first two introns. Another 13 and 16 insertions
Figure 2. Distribution of retroviral inser-
tion sites among mouse chromosomes. The
horizontal lines across the chromosomes in-









F12 4D3 134374117 Tmem57 (F) 35143 (intron 6)
F13 4D3 140187666 Arhgef10l (R) 34261 (intron 1)
F14 6G1 137507993 Eps8 (F) 89813 (intron 2)
F15 8C4 88970931 Abcc12 (F) 133654
F16 8C5 96786499 Nup93 (R) 48019 (intron 3)
F17 8E2 126808432 Galnt2 (F) 53138 (intron 1)
F18 11D 102017387 Tmem101 (F) 288 (intron 1)
F19 12C2 53593700 Arhgap5 (R) 11259
F20 13B2 53640111 Msx2 (F) 71962
F21 13D2.2 115375507 4930544M13Rik (F) 21938
F22 16B1 24237514 Lpp (R) 156062
F23 16C1.1 57420543 Q6P6L0–2 (R) 67153 (intron 1)
The table lists retroviral insertions found in the six iPS clones (A to F) examined. Underlined insertions were found both by bacterial
sequencing and by high throughput sequencing. Genes shown in italics were included in the Ingenuity Pathway Analysis. The orientation of
retroviral vector transcription was designated as forward (F) when it proceeded in the same sense than the tagged gene and reverse (R) when
it pointed in the opposite direction. The distance between the retroviral insertion site and the transcription start site of the closest gene is
shown in the last column. Insertions that occurred within transcription units and their locations are shown in brackets.
304 iPS Retroviral Insertion Siteswere within 10 kb downstream and upstream of the transcription
start site, respectively.
Thirty of the 79 mapped retroviral insertions in iPS
clones are included in the mouse Retrovirus Tagged Cancer
Gene Database (http://rtcgd.abcc.ncifcrf.gov). Importantly,
our data showed that not a single gene was shared by more
than one iPS clone. The two closest insertions identified (B3
and B4) were located 84 kb apart, upstream of the transcrip-
tion start site for gene Col1a2 on chromosome 6. However,
both were found in the same clone. We therefore conclude
that no gene was targeted more than once by retroviral
insertions in the different iPS clones studied, suggesting that
Oct4, Sox2, Klf4, and c-Myc are sufficient to trigger fibro-
blast reprogramming into iPS cells.
No Evidence That Genes Tagged by Retroviral
Insertions Have Shared Gene Functions or Belong
to Common Canonical Pathways or Gene
Networks
Although no common tagged gene was uncovered by map-
ping the insertion sites in iPS cells, it is still possible that
some of the insertions preferentially affect specific gene
functions, gene networks or signaling pathways. To deter-
mine whether retrovirally tagged genes fall into functional
gene categories, the genes listed in Table 1 were grouped
together with Oct4, Sox2, Klf4, and c-Myc and subjected to
bioinformatics analyses using Ingenuity Pathway Analysis
(Ingenuity Systems). The total number of genes so analyzed
was reduced from 79 to 69 since insertions B1 and B4 were
left out (they correspond to the endogenous Klf4 gene and to
Col1a2, which was detected twice), and another 12 genes
were subtracted because not enough biological information
was available. The remaining 69 genes showed no evident
enrichment for any specific gene function (supporting infor-
mation Fig. 4). Similarly, no bias toward any canonical gene
pathway was observed (supporting information Fig. 5). Fi-
nally, the network analysis revealed 18 genes as part of a best
gene network that was enriched in components of nervous
system development and function, cell cycle and cellular
development (supporting information Fig. 6). To assess
whether this network might be biologically relevant or a
product of chance, the Ingenuity Pathway Analysis was re-
peated 50 times with different groups of 65 randomly se-
lected genes plus the four Yamanaka transcription factors.
This analysis revealed that the number of genes participating
in best networks ranged between 13 and 28 (Fig. 3). The
value obtained with the targeted genes from Table 1, 18 gene
functions, therefore falls well within the range of values
obtained with the randomized approach. We conclude that the
retroviral insertions in the six iPS clones studied have no
shared gene functions, nor do they belong to a common
canonical pathway or gene network.
DISCUSSION
Our results show that no genes tagged by retroviral insertions
were repeatedly detected in the six iPS clones analyzed. In
addition, bioinformatics analyses showed no enrichment of
tagged genes that are functionally related or are part of the
same pathways or networks. On the basis of the estimated
numbers of integrations by Southern blotting, bacterial clon-
ing and sequencing, and high-throughput sequencing (sum-
marized in Table 2), the insertion site coverage for the six iPS
clones analyzed appears to be complete. This is reinforced by
the fact that the minimum frequency with which each inser-
tion was sequenced by high throughput was 3–26 times per
amplicon per clone. However, it is possible that the number
of integrations detected using the Tsp509I restriction enzyme
to generate the samples used for high-throughput sequencing
is not exhaustive. Thus, it has been reported that the restric-
tion enzyme used for genomic DNA digestion preceding
PCR-based protocols influences the coverage of retroviral
insertion sites detected [14].
Twelve of the 28 retrovirally tagged genes previously re-
ported in liver and hepatic-derived iPS [12] are included in the
Retrovirus Tagged Cancer Gene Database [15]. Similarly, we
found that an elevated percentage (38%) of the tagged genes in
fibroblast-derived iPS is contained in this database, as three sets
of 69 random control genes yielded 20%. This might represent
a bias of integrations into actively transcribed genes, although a
biological relevance of the enriched genes cannot be excluded.
Importantly, bioinformatic analyses of our data showed no en-
richment of tagged genes that are functionally related or are part
of the same pathway or network. In addition, we found no
overlap between the genes targeted in our study and those
reported by another group [12]. Our results therefore indicate
that Oct4, Sox2, Klf4, and c-Myc are sufficient to induce the
reprogramming of fibroblasts into iPS cells and extend the
observations of Aoi et al. [12] to one of the most commonly
used and easily available cell types used in reprogramming
studies.
There are several alternative explanations for the observed
low frequencies of reprogramming. One possibility is that the
cell type of origin dictates the frequency and that fibroblasts are
heterogeneous, being composed of a few highly susceptible and
many resistant cell types. This is unlikely, since it has been
shown that epithelial cells derived from stomach, liver, and
pancreatic  cells can be reprogrammed by the four Yamanaka
factors, at frequencies similar to or above those seen with
fibroblasts [12, 16]. However, reprogramming of mature B cells
required an additional transcription factor [17]. Another possi-
bility is that the stoichiometry of the Yamanaka factors ex-
Figure 3. Distribution of the number of gene functions included in the
best gene networks of 50 groups of 65 randomly selected genes plus
Oct4, Sox2, Klf4, and c-Myc.










A 15 8 16 (6–185)
b
B 12–14 7 12 (15–169)
C 4–5
a 11 15 (20–317)
D 9 9 13 (26–228)
E 10 9 11 (3–216)
F 14 26 (6–121)
aUnderestimation.
bFrequency of detection.
Abbreviation: iPS, induced pluripotent stem.
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no or incomplete reprogramming, growth disadvantage, or
death.
The most likely scenario, therefore, is that only a small
proportion of somatic cells have a chromatin configuration
amenable to transcription factor-induced changes resulting in
iPS cell formation. Two lines of evidence support this notion.
First, daughter cells derived from a partially reprogrammed iPS
cell clone have been shown to reactivate Oct4 at different times,
consistent with the involvement of stochastic epigenetic events
leading to the reacquisition of pluripotency [18]. Second, the
treatment of partially reprogrammed iPS cells or of somatic cells
undergoing reprogramming with compounds targeting epige-
netic modifications, including DNA and histone methylation as
well as histone acetylation, improves the efficiency and fidelity
of reprogramming significantly [19–21].
CONCLUSION
The analysis of six fibroblast-derived iPS cell clones induced
after infection with retroviruses expressing Oct4, Sox2, Klf4,
and c-Myc showed no evidence of common retroviral integra-
tion sites. Taking these data together with supporting bioinfor-
matics analyses, we suggest that the activation of additional
endogenous genes is not required for the reprogramming in-
duced by the four factors. It will now be interesting to see
whether the four Yamanaka factors are sufficient to generate
viral integration-free iPS cells for research and regenerative
medicine.
NOTE ADDED IN PROOF
Two communications have now shown that the formation of iPS
cells can be generated without using retroviruses as vectors and
in the absence of detectable integrations:
Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka
S. Generation of mouse induced pluripotent stem cells without
viral vectors. Science. 2008;322:949–953.
Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K.
Induced pluripotent stem cells generated without viral integra-
tion. Science. 2008;322:945–949.
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